Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men

Open access
Juusola, Jessie L., Brandeau, Margaret L., Owens, Douglas K., Bendavid, Eran · 2012 · Annals of Internal Medicine

Abstract

BACKGROUND: A recent randomized, controlled trial showed that daily oral preexposure chemoprophylaxis (PrEP) was effective for HIV prevention in men who have sex with men (MSM). The Centers for Disease Control and Prevention recently provided interim guidance for PrEP in MSM at high risk for HIV. Previous studies did not reach a consistent estimate of its cost-effectiveness. OBJECTIVE: To estimate the effectiveness and cost-effectiveness of PrEP in MSM in the United States. DESIGN: Dynamic model of HIV transmission and progression combined with a detailed economic analysis. DATA SOURCES: Published literature. TARGET POPULATION: MSM aged 13 to 64 years in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: PrEP was evaluated in both the general MSM population and in high-risk MSM and was assumed to reduce infection risk by 44% on the basis of clinical trial results. OUTCOME MEASURES: New HIV infections, discounted quality-adjusted life-years (QALYs) and costs, and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Initiating PrEP in 20% of MSM in the United States would reduce new HIV infections by an estimated 13% and result in a gain of 550,166 QALYs over 20 years at a cost of $172,091 per QALY gained. Initiating PrEP in a larger proportion of MSM would prevent more infections but at an increasing cost per QALY gained (up to $216,480 if all MSM receive PrEP). Preexposure chemoprophylaxis in only high-risk MSM can improve cost-effectiveness. For MSM with an average of 5 partners per year, PrEP costs approximately $50,000 per QALY gained. Providing PrEP to all high-risk MSM for 20 years would cost $75 billion more in health care-related costs than the status quo and $600,000 per HIV infection prevented, compared with incremental costs of $95 billion and $2 million per infection prevented for 20% coverage of all MSM. RESULTS OF SENSITIVITY ANALYSIS: PrEP in the general MSM population would cost less than $100,000 per QALY gained if the daily cost of antiretroviral drugs for PrEP was less than $15 or if PrEP efficacy was greater than 75%. LIMITATION: When examining PrEP in high-risk MSM, the investigators did not model a mix of low- and high-risk MSM because of lack of data on mixing patterns. CONCLUSION: PrEP in the general MSM population could prevent a substantial number of HIV infections, but it is expensive. Use in high-risk MSM compares favorably with other interventions that are considered cost-effective but could result in annual PrEP expenditures of more than $4 billion. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse, Department of Veterans Affairs, and National Institute of Allergy and Infectious Diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-156-8-201204170-00001

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 69

  1. Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, 60, 65
  2. 10.1086/597095 · DOI · Paper page
  3. 10.1097/QAD.0b013e32830e00f5 · DOI · Paper page
  4. 10.1097/QAD.0b013e328349f067 · DOI
  5. Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb. Mortal Wkly Rep, 57, 1073
  6. 10.1097/OLQ.0b013e3181ce122b · DOI
  7. Arias E, 2007, Natl Vital Stat Rep, 56, 1
  8. 10.1086/386333 · DOI · Paper page
  9. 10.1016/S0891-5520(05)70135-5 · DOI
  10. 10.1086/590501 · DOI · Paper page
  11. 10.1097/QAD.0b013e32826fb6a6 · DOI
  12. 10.1097/00002030-200406180-00010 · doi:10.1097/00002030-200406180-00010
  13. 10.1016/j.vaccine.2009.06.063 · DOI
  14. 10.7326/0003-4819-126-12-199706150-00003 · DOI · Paper page
  15. 10.1086/524686 · DOI
  16. 10.7326/0003-4819-153-12-201012210-00004 · DOI · Paper page
  17. 10.1097/QAD.0b013e328133f285 · DOI · Paper page
  18. 10.1097/00002030-200305020-00012 · DOI
  19. 10.1086/512816 · DOI
  20. 10.1097/00002030-200207260-00010 · DOI · Paper page
  21. 10.7326/0003-4819-145-6-200609190-00005 · DOI · Paper page
  22. 10.1097/00126334-200404150-00011 · DOI · Paper page
  23. 10.1097/01.aids.0000238410.67700.d1 · DOI
  24. 10.1097/00007435-199808000-00006 · DOI
  25. 10.1056/NEJMsa042657 · DOI · Paper page
  26. 10.1016/S0140-6736(08)61115-0 · DOI · Paper page
  27. 10.1056/NEJM200003303421303 · DOI · Paper page
  28. 10.1126/science.280.5371.1889 · DOI · Paper page
  29. 10.1097/01.qai.0000194234.31078.bf · DOI
  30. 10.7326/0003-4819-146-8-200704170-00010 · DOI · Paper page
  31. Sanchez T, 2006, MMWR Surveill Summ, 55, 1
  32. 10.1007/s11524-006-9135-5 · DOI
  33. 10.1097/QAI.0b013e3181ee4c62 · DOI
  34. 10.1007/s10461-009-9582-6 · DOI
  35. 10.1097/01.qai.0000151079.33935.79 · DOI · Paper page
  36. 10.7326/0003-4819-134-1-200101020-00010 · DOI · Paper page
  37. 10.1056/NEJM200103153441107 · DOI · Paper page
  38. 10.1097/01.mlr.0000228021.89490.2a · DOI · Paper page
  39. 10.1097/00002030-199905280-00013 · DOI
  40. 10.1097/01.qai.0000243090.32866.4e · DOI
  41. 10.1377/hlthaff.23.4.176 · DOI · Paper page
  42. 10.7326/0003-4819-145-11-200612050-00004 · DOI · Paper page
  43. Branson BM, 2006, MMWR Recomm Rep, 55, 1
  44. 10.1001/jama.300.5.555 · DOI · Paper page
  45. 10.1089/apc.2010.0222 · DOI
  46. 10.1007/s11904-010-0057-1 · DOI
  47. 10.1097/QAI.0b013e3181e19a54 · DOI · Paper page
  48. 10.1089/apc.2010.0173 · doi:10.1089/apc.2010.0173
  49. 10.1097/QAI.0b013e31818d5a27 · DOI · Paper page
  50. 10.1097/QAI.0b013e31815e4041 · DOI · Paper page
  51. 10.1007/s11136-005-8485-x · doi:10.1007/s11136-005-8485-x
  52. 10.7326/0003-4819-154-3-201102010-00007 · DOI · Paper page
  53. 10.1371/journal.pmed.1000423 · DOI
  54. 10.1097/00002030-199510000-00001 · DOI
  55. 10.1177/0272989X9301300202 · DOI · Paper page
  56. 10.1001/jama.1997.03550230061038 · DOI
  57. 10.7326/0000605-200912150-00157 · DOI
  58. 10.1016/j.vaccine.2004.12.033 · DOI
  59. 10.1046/j.1524-4733.2003.00213.x · DOI
  60. 10.7326/0003-4819-139-2-200307150-00011 · DOI
  61. 10.1097/00042560-199709010-00009 · DOI · Paper page
  62. 10.1177/0272989X02238300 · DOI · Paper page
  63. 10.1097/MLR.0b013e31803dce05 · DOI
  64. 10.1177/0272989X06290495 · DOI · Paper page
  65. 10.1097/QAD.0b013e328010c7d0 · DOI
  66. 10.1001/archinte.1996.00440040066007 · DOI
  67. 10.1016/S0002-9343(00)00583-0 · doi:10.1016/s0002-9343(00)00583-0
  68. 10.1007/s11908-006-0008-6 · DOI · Paper page
  69. 10.1056/NEJMsa042088 · DOI · Paper page

Cited by

See all 235

Metadata

Authors
Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E.
Venue
Annals of Internal Medicine
Published
2012-04-17
Volume
156
Issue
8
Pages
541-550
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W1981177608
Cited by
235
References
11
FWCI
15.18
Type
journal article
Language
en
Open access
green
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. https://app.cochat.ai/papers/10.7326/0003-4819-156-8-201204170-00001
The paper
Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E. (2012). The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-156-8-201204170-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.